Premium
O4‐05‐03: TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR: A POTENTIAL THERAPEUTIC FOR ALZHEIMER'S DISEASE
Author(s) -
Melchior Ben,
Lai Carolyn,
Duong-Polk Karen,
Tjitro Amanda,
Ince Deniz C.,
Stewart Joshua,
Dellamary Luis,
Hofilena Brian,
Mittapalli Gopi,
KC Sunil,
Yazici Yusuf
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2935
Subject(s) - dyrk1a , hyperphosphorylation , chemistry , kinase , glial fibrillary acidic protein , western blot , neuroinflammation , astrocyte , phosphorylation , pharmacology , immunostaining , microbiology and biotechnology , mapk/erk pathway , endocrinology , biology , pathology , medicine , biochemistry , immunohistochemistry , central nervous system , inflammation , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom